HitGen(SH:688222) Zhong Zheng Wang·2025-11-20 06:53Core Viewpoint - Chengdu XianDao has signed a new agreement with the Gates Foundation to develop new drugs for tuberculosis and malaria, as well as non-hormonal contraceptives, utilizing its DNA-encoded compound library (DEL) technology platform [1] Group 1: Agreement Details - The agreement involves screening for new lead compounds targeting 15 drug targets identified by the Gates Foundation and its academic and research partners [1] - The drug discovery work will receive funding support from the Gates Foundation [1] Group 2: Previous Achievements - Chengdu XianDao previously discovered novel lead compounds for malaria and tuberculosis in a project funded by the Gates Foundation, which serves as the foundation for this new initiative [1] Group 3: Company Profile - Chengdu XianDao aims to become a leading innovative biopharmaceutical company globally and is a leader in the development of DEL technology and its application in small molecule drug discovery [1] - The DEL technology platform contains over 1.2 trillion DNA-encoded compounds, and the company's DEL products and efficient screening capabilities have supported numerous drug discovery projects worldwide [1]